Cargando…

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients

BACKGROUND: Heterozygous familial hypercholesterolemia (HFH) is an autosomal dominant genetic disorder leading to a lifetime exposure to high low-density lipoprotein cholesterol (LDL-c) level and an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). We evaluate the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matta, Anthony, Rabès, Jean Pierre, Taraszkiewicz, Dorota, Carrié, Didier, Roncalli, Jérôme, Ferrières, Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395089/ https://www.ncbi.nlm.nih.gov/pubmed/37539087 http://dx.doi.org/10.3389/fcvm.2023.1182554

Ejemplares similares

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
por: Matta, Anthony, et al.
Publicado: (2021)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia
por: Ferrières, Jean, et al.
Publicado: (2022)

Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) Receptor Abnormalities: A Report of 2 Cases
por: Matta, Anthony, et al.
Publicado: (2020)

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study
por: Barrios, Vivencio, et al.
Publicado: (2022)

Comparison of in-hospital outcomes and long-term survival for valve-in-valve transcatheter aortic valve replacement versus the benchmark native valve transcatheter aortic valve replacement procedure
por: Matta, Anthony, et al.
Publicado: (2023)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease
por: Weintraub, Spencer F., et al.
Publicado: (2022)

Genetic Testing in Familial Hypercholesterolemia: Strengthening the Tools, Reinforcing Efforts, and Diagnosis
por: Abifadel, Marianne S., et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines
por: Gourdy, Pierre, et al.
Publicado: (2023)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Familial Hypercholesterolemia and the Atherosclerotic Disease
por: Kim, Yoo Ri, et al.
Publicado: (2013)

Correlation of cardiovascular risk predictors with overweight and obesity in patients with familial hypercholesterolemia
por: Wang, Yaodong, et al.
Publicado: (2022)

Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease
por: Trinder, Mark, et al.
Publicado: (2020)

Case Report: Difficulties in the Treatment of a 12-Year-Old Patient With Homozygous Familial Hypercholesterolemia, Compound Heterozygous Form − 5 Years Follow-Up
por: Vladimirova-Kitova, Lyudmila, et al.
Publicado: (2021)

Molecular Spectrum of Autosomal Dominant Hypercholesterolemia in France
por: Marduel, Marie, et al.
Publicado: (2010)

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Naito, Ryo, et al.
Publicado: (2022)

The Spectrum of B Cell Functions in Atherosclerotic Cardiovascular Disease
por: Smeets, Diede, et al.
Publicado: (2022)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Long‐Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening
por: Kjærgaard, Kasper Aalbæk, et al.
Publicado: (2017)

Coronary artery aneurysm: A review
por: Matta, Anthony Georges, et al.
Publicado: (2021)

An infant with a heterozygous variant of ABCG5 presented with hypercholesterolemia only during breastfeeding
por: Yoshida, Aya, et al.
Publicado: (2023)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
por: Chen, Chi-Chang, et al.
Publicado: (2018)

Association Between Periodontal Disease and Atherosclerotic Cardiovascular Diseases: Revisited
por: Zardawi, Faraedon, et al.
Publicado: (2021)

Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the heart of the issue
por: Gabbiadini, Roberto, et al.
Publicado: (2023)

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
por: Toth, Peter P., et al.
Publicado: (2023)

Benefits of Interventional Telemonitoring on Survival and Unplanned Hospitalization in Patients With Chronic Heart Failure
por: Galinier, Michel, et al.
Publicado: (2022)

Association of Hepatic Lipase -514T Allele with Coronary Artery Disease and Ankle-Brachial Index, Dependence on the Lipoprotein Phenotype: The GENES Study
por: Verdier, Céline, et al.
Publicado: (2013)

E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease
por: Poels, Kikkie, et al.
Publicado: (2020)

Paeonol for the Treatment of Atherosclerotic Cardiovascular Disease: A Pharmacological and Mechanistic Overview
por: Wu, Min, et al.
Publicado: (2021)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment
por: Wang, Kexin, et al.
Publicado: (2022)

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
por: Finney, Alexandra C., et al.
Publicado: (2023)

Common variable immunodeficiency—an independent risk factor for atherosclerotic cardiovascular diseases
por: Mattila, Juho, et al.
Publicado: (2023)

Heterozygous Familial Hypercholesterolemia With APOE Haplotype: A Prospective Harbinger of a Catastrophic Cardiovascular Event
por: Lasam, Glenmore, et al.
Publicado: (2017)

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
por: Ershova, Alexandra I., et al.
Publicado: (2016)

Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia
por: Michikura, Masahito, et al.
Publicado: (2022)

Can We Clarify the Causative Gene/Variants Underlying Familial Hypercholesterolemia and Improve Genetic Diagnosis Rate?
por: Hori, Mika
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c3rd94pmkv3meq0jn1rpbtbcf0